Global Gastric Carcinomas Drugs Market Research Report 2026(Status and Outlook)
From a product-type perspective, gastric cancer therapies can be broadly categorized into chemical drugs (including traditional cytotoxic chemotherapies and small-molecule targeted agents) and biologics (monoclonal antibodies, antibody?drug conjugates and immune checkpoint inhibitors, etc.). The former, represented by 5-FU, capecitabine, S-1, platinum agents and small-molecule TKIs such as apatinib, still constitute the backbone of gastric cancer treatment worldwide; the latter, including HER2-targeted antibodies/ADCs, VEGFR-2 antibodies, PD-1/PD-L1 inhibitors and CLDN18.2-targeted antibodies, provides more precise, biomarker-driven options for selected patient subgroups.Gastric cancer therapeutics are rapidly evolving from traditional cytotoxic chemotherapy toward an integrated ?chemicals + biologics + precision segmentation? solution market. On the global stage, Keytruda? (pembrolizumab) from Merck, a PD-1 inhibitor, has been approved in Europe and the US in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 positivity and HER2 negativity, significantly improving overall survival and response rates. At the same time, Herceptin? (trastuzumab) from Roche combined with chemotherapy has become the standard first-line regimen for HER2-positive metastatic gastric and GEJ cancer, providing a clearly defined benefit pathway for the approximately 15?20% of patients with HER2 overexpression.In China, domestic innovative biopharma companies are penetrating gastric cancer sub-segments through differentiated pipelines. Apatinib (Aitan?) from Jiangsu Hengrui Medicine, a small-molecule VEGFR-2 TKI, is the first targeted agent approved in China for third-line and later treatment of advanced gastric or GEJ adenocarcinoma after failure of at least two prior systemic regimens, providing many late-stage patients with an oral maintenance and ?last-resort? option. Disitamab vedotin (RC48, Aidixi?) from RemeGen, a HER2-targeted ADC, has been conditionally approved by the NMPA for locally advanced or metastatic HER2-overexpressing gastric or GEJ cancer previously treated with multiple lines of systemic therapy, becoming the first domestically developed ADC to be approved with gastric cancer as its lead indication. Together with Tevimbra? (tislelizumab) from BeiGene, a PD-1 antibody already approved overseas for first-line gastric cancer, Chinese companies are building a comprehensive treatment continuum from first- to third-line and beyond through a combination strategy of ?chemotherapy backbone + small-molecule targeted therapy + PD-1 inhibitors + ADCs,? finely covering different subpopulations such as HER2-positive, VEGFR-driven, and PD-L1-positive patients. Overall, the gastric cancer drug market is increasingly characterized by a pattern in which leading multinational companies define the molecular-segmented standards, while domestic innovators rapidly fill gaps and create new clinical scenarios, and in the coming years, combination and sequential regimens centered on HER2, VEGFR, PD-1/PD-L1 and CLDN18.2 will continue to raise barriers to entry and represent the core growth drivers for investment and industrial deployment.
The global Gastric Carcinomas Drugs market size was estimated at USD 4942.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Gastric Carcinomas Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Gastric Carcinomas Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Gastric Carcinomas Drugs market.
Global Gastric Carcinomas Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Taiho Pharmaceutical
Genentech (Roche)
Sanofi
Eli Lilly
Astellas Pharma
Bristol Myers Squibb
Merck & Co., Inc
BeiGene
Jiangsu Hengrui
RemeGen
Daiichi Sankyo + AstraZeneca
Market Segmentation (by Type)
Cytotoxic Chemotherapy
HER2-Targeted Therapy
VEGF/VEGFR-Targeted Therapy
PD-1/PD-L1
Others
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Gastric Carcinomas Drugs Market
Overview of the regional outlook of the Gastric Carcinomas Drugs Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Gastric Carcinomas Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Gastric Carcinomas Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Gastric Carcinomas Drugs market size was estimated at USD 4942.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.60% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Gastric Carcinomas Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Gastric Carcinomas Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Gastric Carcinomas Drugs market.
Global Gastric Carcinomas Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Taiho Pharmaceutical
Genentech (Roche)
Sanofi
Eli Lilly
Astellas Pharma
Bristol Myers Squibb
Merck & Co., Inc
BeiGene
Jiangsu Hengrui
RemeGen
Daiichi Sankyo + AstraZeneca
Market Segmentation (by Type)
Cytotoxic Chemotherapy
HER2-Targeted Therapy
VEGF/VEGFR-Targeted Therapy
PD-1/PD-L1
Others
Market Segmentation (by Application)
Hospital
Clinic
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Gastric Carcinomas Drugs Market
Overview of the regional outlook of the Gastric Carcinomas Drugs Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Gastric Carcinomas Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Gastric Carcinomas Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Gastric Carcinomas Drugs
1.2 Key Market Segments
1.2.1 Gastric Carcinomas Drugs Segment by Type
1.2.2 Gastric Carcinomas Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GASTRIC CARCINOMAS DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Gastric Carcinomas Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Gastric Carcinomas Drugs Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GASTRIC CARCINOMAS DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Gastric Carcinomas Drugs Product Life Cycle
3.3 Global Gastric Carcinomas Drugs Sales by Manufacturers (2020-2025)
3.4 Global Gastric Carcinomas Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Gastric Carcinomas Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Gastric Carcinomas Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Gastric Carcinomas Drugs Market Competitive Situation and Trends
3.8.1 Gastric Carcinomas Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Gastric Carcinomas Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 GASTRIC CARCINOMAS DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Gastric Carcinomas Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GASTRIC CARCINOMAS DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Gastric Carcinomas Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Gastric Carcinomas Drugs Market
5.7 ESG Ratings of Leading Companies
6 GASTRIC CARCINOMAS DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Gastric Carcinomas Drugs Sales Market Share by Type (2020-2025)
6.3 Global Gastric Carcinomas Drugs Market Size by Type (2020-2025)
6.4 Global Gastric Carcinomas Drugs Price by Type (2020-2025)
7 GASTRIC CARCINOMAS DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Gastric Carcinomas Drugs Market Sales by Application (2020-2025)
7.3 Global Gastric Carcinomas Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
8 GASTRIC CARCINOMAS DRUGS MARKET SALES BY REGION
8.1 Global Gastric Carcinomas Drugs Sales by Region
8.1.1 Global Gastric Carcinomas Drugs Sales by Region
8.1.2 Global Gastric Carcinomas Drugs Sales Market Share by Region
8.2 Global Gastric Carcinomas Drugs Market Size by Region
8.2.1 Global Gastric Carcinomas Drugs Market Size by Region
8.2.2 Global Gastric Carcinomas Drugs Market Size by Region
8.3 North America
8.3.1 North America Gastric Carcinomas Drugs Sales by Country
8.3.2 North America Gastric Carcinomas Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Gastric Carcinomas Drugs Sales by Country
8.4.2 Europe Gastric Carcinomas Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Gastric Carcinomas Drugs Sales by Region
8.5.2 Asia Pacific Gastric Carcinomas Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Gastric Carcinomas Drugs Sales by Country
8.6.2 South America Gastric Carcinomas Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Gastric Carcinomas Drugs Sales by Region
8.7.2 Middle East and Africa Gastric Carcinomas Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 GASTRIC CARCINOMAS DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Gastric Carcinomas Drugs by Region(2020-2025)
9.2 Global Gastric Carcinomas Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Gastric Carcinomas Drugs Production
9.4.1 North America Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.4.2 North America Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Gastric Carcinomas Drugs Production
9.5.1 Europe Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Gastric Carcinomas Drugs Production (2020-2025)
9.6.1 Japan Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Gastric Carcinomas Drugs Production (2020-2025)
9.7.1 China Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.7.2 China Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Taiho Pharmaceutical
10.1.1 Taiho Pharmaceutical Basic Information
10.1.2 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Overview
10.1.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Market Performance
10.1.4 Taiho Pharmaceutical Business Overview
10.1.5 Taiho Pharmaceutical SWOT Analysis
10.1.6 Taiho Pharmaceutical Recent Developments
10.2 Genentech (Roche)
10.2.1 Genentech (Roche) Basic Information
10.2.2 Genentech (Roche) Gastric Carcinomas Drugs Product Overview
10.2.3 Genentech (Roche) Gastric Carcinomas Drugs Product Market Performance
10.2.4 Genentech (Roche) Business Overview
10.2.5 Genentech (Roche) SWOT Analysis
10.2.6 Genentech (Roche) Recent Developments
10.3 Sanofi
10.3.1 Sanofi Basic Information
10.3.2 Sanofi Gastric Carcinomas Drugs Product Overview
10.3.3 Sanofi Gastric Carcinomas Drugs Product Market Performance
10.3.4 Sanofi Business Overview
10.3.5 Sanofi SWOT Analysis
10.3.6 Sanofi Recent Developments
10.4 Eli Lilly
10.4.1 Eli Lilly Basic Information
10.4.2 Eli Lilly Gastric Carcinomas Drugs Product Overview
10.4.3 Eli Lilly Gastric Carcinomas Drugs Product Market Performance
10.4.4 Eli Lilly Business Overview
10.4.5 Eli Lilly Recent Developments
10.5 Astellas Pharma
10.5.1 Astellas Pharma Basic Information
10.5.2 Astellas Pharma Gastric Carcinomas Drugs Product Overview
10.5.3 Astellas Pharma Gastric Carcinomas Drugs Product Market Performance
10.5.4 Astellas Pharma Business Overview
10.5.5 Astellas Pharma Recent Developments
10.6 Bristol Myers Squibb
10.6.1 Bristol Myers Squibb Basic Information
10.6.2 Bristol Myers Squibb Gastric Carcinomas Drugs Product Overview
10.6.3 Bristol Myers Squibb Gastric Carcinomas Drugs Product Market Performance
10.6.4 Bristol Myers Squibb Business Overview
10.6.5 Bristol Myers Squibb Recent Developments
10.7 Merck and Co., Inc
10.7.1 Merck and Co., Inc Basic Information
10.7.2 Merck and Co., Inc Gastric Carcinomas Drugs Product Overview
10.7.3 Merck and Co., Inc Gastric Carcinomas Drugs Product Market Performance
10.7.4 Merck and Co., Inc Business Overview
10.7.5 Merck and Co., Inc Recent Developments
10.8 BeiGene
10.8.1 BeiGene Basic Information
10.8.2 BeiGene Gastric Carcinomas Drugs Product Overview
10.8.3 BeiGene Gastric Carcinomas Drugs Product Market Performance
10.8.4 BeiGene Business Overview
10.8.5 BeiGene Recent Developments
10.9 Jiangsu Hengrui
10.9.1 Jiangsu Hengrui Basic Information
10.9.2 Jiangsu Hengrui Gastric Carcinomas Drugs Product Overview
10.9.3 Jiangsu Hengrui Gastric Carcinomas Drugs Product Market Performance
10.9.4 Jiangsu Hengrui Business Overview
10.9.5 Jiangsu Hengrui Recent Developments
10.10 RemeGen
10.10.1 RemeGen Basic Information
10.10.2 RemeGen Gastric Carcinomas Drugs Product Overview
10.10.3 RemeGen Gastric Carcinomas Drugs Product Market Performance
10.10.4 RemeGen Business Overview
10.10.5 RemeGen Recent Developments
10.11 Daiichi Sankyo + AstraZeneca
10.11.1 Daiichi Sankyo + AstraZeneca Basic Information
10.11.2 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Overview
10.11.3 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Market Performance
10.11.4 Daiichi Sankyo + AstraZeneca Business Overview
10.11.5 Daiichi Sankyo + AstraZeneca Recent Developments
11 GASTRIC CARCINOMAS DRUGS MARKET FORECAST BY REGION
11.1 Global Gastric Carcinomas Drugs Market Size Forecast
11.2 Global Gastric Carcinomas Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Gastric Carcinomas Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Gastric Carcinomas Drugs Market Size Forecast by Region
11.2.4 South America Gastric Carcinomas Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Gastric Carcinomas Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Gastric Carcinomas Drugs Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Gastric Carcinomas Drugs by Type (2026-2035)
12.1.2 Global Gastric Carcinomas Drugs Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Gastric Carcinomas Drugs by Type (2026-2035)
12.2 Global Gastric Carcinomas Drugs Market Forecast by Application (2026-2035)
12.2.1 Global Gastric Carcinomas Drugs Sales (K MT) Forecast by Application
12.2.2 Global Gastric Carcinomas Drugs Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Gastric Carcinomas Drugs
1.2 Key Market Segments
1.2.1 Gastric Carcinomas Drugs Segment by Type
1.2.2 Gastric Carcinomas Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GASTRIC CARCINOMAS DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Gastric Carcinomas Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Gastric Carcinomas Drugs Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GASTRIC CARCINOMAS DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Gastric Carcinomas Drugs Product Life Cycle
3.3 Global Gastric Carcinomas Drugs Sales by Manufacturers (2020-2025)
3.4 Global Gastric Carcinomas Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Gastric Carcinomas Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Gastric Carcinomas Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Gastric Carcinomas Drugs Market Competitive Situation and Trends
3.8.1 Gastric Carcinomas Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Gastric Carcinomas Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 GASTRIC CARCINOMAS DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Gastric Carcinomas Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GASTRIC CARCINOMAS DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Gastric Carcinomas Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Gastric Carcinomas Drugs Market
5.7 ESG Ratings of Leading Companies
6 GASTRIC CARCINOMAS DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Gastric Carcinomas Drugs Sales Market Share by Type (2020-2025)
6.3 Global Gastric Carcinomas Drugs Market Size by Type (2020-2025)
6.4 Global Gastric Carcinomas Drugs Price by Type (2020-2025)
7 GASTRIC CARCINOMAS DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Gastric Carcinomas Drugs Market Sales by Application (2020-2025)
7.3 Global Gastric Carcinomas Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
8 GASTRIC CARCINOMAS DRUGS MARKET SALES BY REGION
8.1 Global Gastric Carcinomas Drugs Sales by Region
8.1.1 Global Gastric Carcinomas Drugs Sales by Region
8.1.2 Global Gastric Carcinomas Drugs Sales Market Share by Region
8.2 Global Gastric Carcinomas Drugs Market Size by Region
8.2.1 Global Gastric Carcinomas Drugs Market Size by Region
8.2.2 Global Gastric Carcinomas Drugs Market Size by Region
8.3 North America
8.3.1 North America Gastric Carcinomas Drugs Sales by Country
8.3.2 North America Gastric Carcinomas Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Gastric Carcinomas Drugs Sales by Country
8.4.2 Europe Gastric Carcinomas Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Gastric Carcinomas Drugs Sales by Region
8.5.2 Asia Pacific Gastric Carcinomas Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Gastric Carcinomas Drugs Sales by Country
8.6.2 South America Gastric Carcinomas Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Gastric Carcinomas Drugs Sales by Region
8.7.2 Middle East and Africa Gastric Carcinomas Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 GASTRIC CARCINOMAS DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Gastric Carcinomas Drugs by Region(2020-2025)
9.2 Global Gastric Carcinomas Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Gastric Carcinomas Drugs Production
9.4.1 North America Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.4.2 North America Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Gastric Carcinomas Drugs Production
9.5.1 Europe Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Gastric Carcinomas Drugs Production (2020-2025)
9.6.1 Japan Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Gastric Carcinomas Drugs Production (2020-2025)
9.7.1 China Gastric Carcinomas Drugs Production Growth Rate (2020-2025)
9.7.2 China Gastric Carcinomas Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Taiho Pharmaceutical
10.1.1 Taiho Pharmaceutical Basic Information
10.1.2 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Overview
10.1.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Market Performance
10.1.4 Taiho Pharmaceutical Business Overview
10.1.5 Taiho Pharmaceutical SWOT Analysis
10.1.6 Taiho Pharmaceutical Recent Developments
10.2 Genentech (Roche)
10.2.1 Genentech (Roche) Basic Information
10.2.2 Genentech (Roche) Gastric Carcinomas Drugs Product Overview
10.2.3 Genentech (Roche) Gastric Carcinomas Drugs Product Market Performance
10.2.4 Genentech (Roche) Business Overview
10.2.5 Genentech (Roche) SWOT Analysis
10.2.6 Genentech (Roche) Recent Developments
10.3 Sanofi
10.3.1 Sanofi Basic Information
10.3.2 Sanofi Gastric Carcinomas Drugs Product Overview
10.3.3 Sanofi Gastric Carcinomas Drugs Product Market Performance
10.3.4 Sanofi Business Overview
10.3.5 Sanofi SWOT Analysis
10.3.6 Sanofi Recent Developments
10.4 Eli Lilly
10.4.1 Eli Lilly Basic Information
10.4.2 Eli Lilly Gastric Carcinomas Drugs Product Overview
10.4.3 Eli Lilly Gastric Carcinomas Drugs Product Market Performance
10.4.4 Eli Lilly Business Overview
10.4.5 Eli Lilly Recent Developments
10.5 Astellas Pharma
10.5.1 Astellas Pharma Basic Information
10.5.2 Astellas Pharma Gastric Carcinomas Drugs Product Overview
10.5.3 Astellas Pharma Gastric Carcinomas Drugs Product Market Performance
10.5.4 Astellas Pharma Business Overview
10.5.5 Astellas Pharma Recent Developments
10.6 Bristol Myers Squibb
10.6.1 Bristol Myers Squibb Basic Information
10.6.2 Bristol Myers Squibb Gastric Carcinomas Drugs Product Overview
10.6.3 Bristol Myers Squibb Gastric Carcinomas Drugs Product Market Performance
10.6.4 Bristol Myers Squibb Business Overview
10.6.5 Bristol Myers Squibb Recent Developments
10.7 Merck and Co., Inc
10.7.1 Merck and Co., Inc Basic Information
10.7.2 Merck and Co., Inc Gastric Carcinomas Drugs Product Overview
10.7.3 Merck and Co., Inc Gastric Carcinomas Drugs Product Market Performance
10.7.4 Merck and Co., Inc Business Overview
10.7.5 Merck and Co., Inc Recent Developments
10.8 BeiGene
10.8.1 BeiGene Basic Information
10.8.2 BeiGene Gastric Carcinomas Drugs Product Overview
10.8.3 BeiGene Gastric Carcinomas Drugs Product Market Performance
10.8.4 BeiGene Business Overview
10.8.5 BeiGene Recent Developments
10.9 Jiangsu Hengrui
10.9.1 Jiangsu Hengrui Basic Information
10.9.2 Jiangsu Hengrui Gastric Carcinomas Drugs Product Overview
10.9.3 Jiangsu Hengrui Gastric Carcinomas Drugs Product Market Performance
10.9.4 Jiangsu Hengrui Business Overview
10.9.5 Jiangsu Hengrui Recent Developments
10.10 RemeGen
10.10.1 RemeGen Basic Information
10.10.2 RemeGen Gastric Carcinomas Drugs Product Overview
10.10.3 RemeGen Gastric Carcinomas Drugs Product Market Performance
10.10.4 RemeGen Business Overview
10.10.5 RemeGen Recent Developments
10.11 Daiichi Sankyo + AstraZeneca
10.11.1 Daiichi Sankyo + AstraZeneca Basic Information
10.11.2 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Overview
10.11.3 Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Market Performance
10.11.4 Daiichi Sankyo + AstraZeneca Business Overview
10.11.5 Daiichi Sankyo + AstraZeneca Recent Developments
11 GASTRIC CARCINOMAS DRUGS MARKET FORECAST BY REGION
11.1 Global Gastric Carcinomas Drugs Market Size Forecast
11.2 Global Gastric Carcinomas Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Gastric Carcinomas Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Gastric Carcinomas Drugs Market Size Forecast by Region
11.2.4 South America Gastric Carcinomas Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Gastric Carcinomas Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Gastric Carcinomas Drugs Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Gastric Carcinomas Drugs by Type (2026-2035)
12.1.2 Global Gastric Carcinomas Drugs Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Gastric Carcinomas Drugs by Type (2026-2035)
12.2 Global Gastric Carcinomas Drugs Market Forecast by Application (2026-2035)
12.2.1 Global Gastric Carcinomas Drugs Sales (K MT) Forecast by Application
12.2.2 Global Gastric Carcinomas Drugs Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Gastric Carcinomas Drugs Market Size by Type (M USD)
Table 4. Global Gastric Carcinomas Drugs Market Size by Application
Table 5. Gastric Carcinomas Drugs Market Size Comparison by Region (M USD)
Table 6. Global Gastric Carcinomas Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Gastric Carcinomas Drugs Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Gastric Carcinomas Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Gastric Carcinomas Drugs Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2025)
Table 11. Global Market Gastric Carcinomas Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Gastric Carcinomas Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Gastric Carcinomas Drugs Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Gastric Carcinomas Drugs Sales by Type (K MT)
Table 27. Global Gastric Carcinomas Drugs Market Size by Type (M USD)
Table 28. Global Gastric Carcinomas Drugs Sales (K MT) by Type (2020-2025)
Table 29. Global Gastric Carcinomas Drugs Sales Market Share by Type (2020-2025)
Table 30. Global Gastric Carcinomas Drugs Market Size (M USD) by Type (2020-2025)
Table 31. Global Gastric Carcinomas Drugs Market Share by Type (2020-2025)
Table 32. Global Gastric Carcinomas Drugs Price (USD/KG) by Type (2020-2025)
Table 33. Global Gastric Carcinomas Drugs Sales (K MT) by Application
Table 34. Global Gastric Carcinomas Drugs Market Size by Application
Table 35. Global Gastric Carcinomas Drugs Sales by Application (2020-2025) & (K MT)
Table 36. Global Gastric Carcinomas Drugs Sales Market Share by Application (2020-2025)
Table 37. Global Gastric Carcinomas Drugs Market Size by Application (2020-2025) & (M USD)
Table 38. Global Gastric Carcinomas Drugs Market Share by Application (2020-2025)
Table 39. Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
Table 40. Global Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 41. Global Gastric Carcinomas Drugs Sales Market Share by Region (2020-2025)
Table 42. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 43. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025)
Table 44. North America Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 45. North America Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 47. Europe Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 50. South America Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 51. South America Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 54. Global Gastric Carcinomas Drugs Production (K MT) by Region(2020-2025)
Table 55. Global Gastric Carcinomas Drugs Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Gastric Carcinomas Drugs Revenue Market Share by Region (2020-2025)
Table 57. Global Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Taiho Pharmaceutical Basic Information
Table 63. Taiho Pharmaceutical Gastric Carcinomas Drugs Product Overview
Table 64. Taiho Pharmaceutical Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Taiho Pharmaceutical Business Overview
Table 66. Taiho Pharmaceutical SWOT Analysis
Table 67. Taiho Pharmaceutical Recent Developments
Table 68. Genentech (Roche) Basic Information
Table 69. Genentech (Roche) Gastric Carcinomas Drugs Product Overview
Table 70. Genentech (Roche) Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Genentech (Roche) Business Overview
Table 72. Genentech (Roche) SWOT Analysis
Table 73. Genentech (Roche) Recent Developments
Table 74. Sanofi Basic Information
Table 75. Sanofi Gastric Carcinomas Drugs Product Overview
Table 76. Sanofi Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Sanofi Business Overview
Table 78. Sanofi SWOT Analysis
Table 79. Sanofi Recent Developments
Table 80. Eli Lilly Basic Information
Table 81. Eli Lilly Gastric Carcinomas Drugs Product Overview
Table 82. Eli Lilly Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Eli Lilly Business Overview
Table 84. Eli Lilly Recent Developments
Table 85. Astellas Pharma Basic Information
Table 86. Astellas Pharma Gastric Carcinomas Drugs Product Overview
Table 87. Astellas Pharma Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Astellas Pharma Business Overview
Table 89. Astellas Pharma Recent Developments
Table 90. Bristol Myers Squibb Basic Information
Table 91. Bristol Myers Squibb Gastric Carcinomas Drugs Product Overview
Table 92. Bristol Myers Squibb Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bristol Myers Squibb Business Overview
Table 94. Bristol Myers Squibb Recent Developments
Table 95. Merck and Co., Inc Basic Information
Table 96. Merck and Co., Inc Gastric Carcinomas Drugs Product Overview
Table 97. Merck and Co., Inc Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Merck and Co., Inc Business Overview
Table 99. Merck and Co., Inc Recent Developments
Table 100. BeiGene Basic Information
Table 101. BeiGene Gastric Carcinomas Drugs Product Overview
Table 102. BeiGene Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. BeiGene Business Overview
Table 104. BeiGene Recent Developments
Table 105. Jiangsu Hengrui Basic Information
Table 106. Jiangsu Hengrui Gastric Carcinomas Drugs Product Overview
Table 107. Jiangsu Hengrui Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Jiangsu Hengrui Business Overview
Table 109. Jiangsu Hengrui Recent Developments
Table 110. RemeGen Basic Information
Table 111. RemeGen Gastric Carcinomas Drugs Product Overview
Table 112. RemeGen Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. RemeGen Business Overview
Table 114. RemeGen Recent Developments
Table 115. Daiichi Sankyo + AstraZeneca Basic Information
Table 116. Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Overview
Table 117. Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Daiichi Sankyo + AstraZeneca Business Overview
Table 119. Daiichi Sankyo + AstraZeneca Recent Developments
Table 120. Global Gastric Carcinomas Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 121. Global Gastric Carcinomas Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 122. North America Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 123. North America Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 124. Europe Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 125. Europe Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 126. Asia Pacific Gastric Carcinomas Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 127. Asia Pacific Gastric Carcinomas Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 128. South America Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 129. South America Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 130. Middle East and Africa Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (Units)
Table 131. Middle East and Africa Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 132. Global Gastric Carcinomas Drugs Sales Forecast by Type (2026-2035) & (K MT)
Table 133. Global Gastric Carcinomas Drugs Market Size Forecast by Type (2026-2035) & (M USD)
Table 134. Global Gastric Carcinomas Drugs Price Forecast by Type (2026-2035) & (USD/KG)
Table 135. Global Gastric Carcinomas Drugs Sales (K MT) Forecast by Application (2026-2035)
Table 136. Global Gastric Carcinomas Drugs Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Gastric Carcinomas Drugs Market Size by Type (M USD)
Table 4. Global Gastric Carcinomas Drugs Market Size by Application
Table 5. Gastric Carcinomas Drugs Market Size Comparison by Region (M USD)
Table 6. Global Gastric Carcinomas Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Gastric Carcinomas Drugs Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Gastric Carcinomas Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Gastric Carcinomas Drugs Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2025)
Table 11. Global Market Gastric Carcinomas Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Gastric Carcinomas Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Gastric Carcinomas Drugs Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Gastric Carcinomas Drugs Sales by Type (K MT)
Table 27. Global Gastric Carcinomas Drugs Market Size by Type (M USD)
Table 28. Global Gastric Carcinomas Drugs Sales (K MT) by Type (2020-2025)
Table 29. Global Gastric Carcinomas Drugs Sales Market Share by Type (2020-2025)
Table 30. Global Gastric Carcinomas Drugs Market Size (M USD) by Type (2020-2025)
Table 31. Global Gastric Carcinomas Drugs Market Share by Type (2020-2025)
Table 32. Global Gastric Carcinomas Drugs Price (USD/KG) by Type (2020-2025)
Table 33. Global Gastric Carcinomas Drugs Sales (K MT) by Application
Table 34. Global Gastric Carcinomas Drugs Market Size by Application
Table 35. Global Gastric Carcinomas Drugs Sales by Application (2020-2025) & (K MT)
Table 36. Global Gastric Carcinomas Drugs Sales Market Share by Application (2020-2025)
Table 37. Global Gastric Carcinomas Drugs Market Size by Application (2020-2025) & (M USD)
Table 38. Global Gastric Carcinomas Drugs Market Share by Application (2020-2025)
Table 39. Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
Table 40. Global Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 41. Global Gastric Carcinomas Drugs Sales Market Share by Region (2020-2025)
Table 42. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 43. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025)
Table 44. North America Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 45. North America Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 47. Europe Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 50. South America Gastric Carcinomas Drugs Sales by Country (2020-2025) & (K MT)
Table 51. South America Gastric Carcinomas Drugs Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Gastric Carcinomas Drugs Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Gastric Carcinomas Drugs Market Size by Region (2020-2025) & (M USD)
Table 54. Global Gastric Carcinomas Drugs Production (K MT) by Region(2020-2025)
Table 55. Global Gastric Carcinomas Drugs Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Gastric Carcinomas Drugs Revenue Market Share by Region (2020-2025)
Table 57. Global Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Gastric Carcinomas Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Taiho Pharmaceutical Basic Information
Table 63. Taiho Pharmaceutical Gastric Carcinomas Drugs Product Overview
Table 64. Taiho Pharmaceutical Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Taiho Pharmaceutical Business Overview
Table 66. Taiho Pharmaceutical SWOT Analysis
Table 67. Taiho Pharmaceutical Recent Developments
Table 68. Genentech (Roche) Basic Information
Table 69. Genentech (Roche) Gastric Carcinomas Drugs Product Overview
Table 70. Genentech (Roche) Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Genentech (Roche) Business Overview
Table 72. Genentech (Roche) SWOT Analysis
Table 73. Genentech (Roche) Recent Developments
Table 74. Sanofi Basic Information
Table 75. Sanofi Gastric Carcinomas Drugs Product Overview
Table 76. Sanofi Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Sanofi Business Overview
Table 78. Sanofi SWOT Analysis
Table 79. Sanofi Recent Developments
Table 80. Eli Lilly Basic Information
Table 81. Eli Lilly Gastric Carcinomas Drugs Product Overview
Table 82. Eli Lilly Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Eli Lilly Business Overview
Table 84. Eli Lilly Recent Developments
Table 85. Astellas Pharma Basic Information
Table 86. Astellas Pharma Gastric Carcinomas Drugs Product Overview
Table 87. Astellas Pharma Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Astellas Pharma Business Overview
Table 89. Astellas Pharma Recent Developments
Table 90. Bristol Myers Squibb Basic Information
Table 91. Bristol Myers Squibb Gastric Carcinomas Drugs Product Overview
Table 92. Bristol Myers Squibb Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bristol Myers Squibb Business Overview
Table 94. Bristol Myers Squibb Recent Developments
Table 95. Merck and Co., Inc Basic Information
Table 96. Merck and Co., Inc Gastric Carcinomas Drugs Product Overview
Table 97. Merck and Co., Inc Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Merck and Co., Inc Business Overview
Table 99. Merck and Co., Inc Recent Developments
Table 100. BeiGene Basic Information
Table 101. BeiGene Gastric Carcinomas Drugs Product Overview
Table 102. BeiGene Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. BeiGene Business Overview
Table 104. BeiGene Recent Developments
Table 105. Jiangsu Hengrui Basic Information
Table 106. Jiangsu Hengrui Gastric Carcinomas Drugs Product Overview
Table 107. Jiangsu Hengrui Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Jiangsu Hengrui Business Overview
Table 109. Jiangsu Hengrui Recent Developments
Table 110. RemeGen Basic Information
Table 111. RemeGen Gastric Carcinomas Drugs Product Overview
Table 112. RemeGen Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. RemeGen Business Overview
Table 114. RemeGen Recent Developments
Table 115. Daiichi Sankyo + AstraZeneca Basic Information
Table 116. Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Product Overview
Table 117. Daiichi Sankyo + AstraZeneca Gastric Carcinomas Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Daiichi Sankyo + AstraZeneca Business Overview
Table 119. Daiichi Sankyo + AstraZeneca Recent Developments
Table 120. Global Gastric Carcinomas Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 121. Global Gastric Carcinomas Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 122. North America Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 123. North America Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 124. Europe Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 125. Europe Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 126. Asia Pacific Gastric Carcinomas Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 127. Asia Pacific Gastric Carcinomas Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 128. South America Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 129. South America Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 130. Middle East and Africa Gastric Carcinomas Drugs Sales Forecast by Country (2026-2035) & (Units)
Table 131. Middle East and Africa Gastric Carcinomas Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 132. Global Gastric Carcinomas Drugs Sales Forecast by Type (2026-2035) & (K MT)
Table 133. Global Gastric Carcinomas Drugs Market Size Forecast by Type (2026-2035) & (M USD)
Table 134. Global Gastric Carcinomas Drugs Price Forecast by Type (2026-2035) & (USD/KG)
Table 135. Global Gastric Carcinomas Drugs Sales (K MT) Forecast by Application (2026-2035)
Table 136. Global Gastric Carcinomas Drugs Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Gastric Carcinomas Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Gastric Carcinomas Drugs Market Size (M USD), 2025-2035
Figure 5. Global Gastric Carcinomas Drugs Market Size (M USD) (2020-2035)
Figure 6. Global Gastric Carcinomas Drugs Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Gastric Carcinomas Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Gastric Carcinomas Drugs Product Life Cycle
Figure 13. Gastric Carcinomas Drugs Sales Share by Manufacturers in 2025
Figure 14. Global Gastric Carcinomas Drugs Revenue Share by Manufacturers in 2025
Figure 15. Gastric Carcinomas Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Gastric Carcinomas Drugs Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Gastric Carcinomas Drugs Revenue in 2025
Figure 18. Industry Chain Map of Gastric Carcinomas Drugs
Figure 19. Global Gastric Carcinomas Drugs Market PEST Analysis
Figure 20. Global Gastric Carcinomas Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Gastric Carcinomas Drugs Market Share by Type
Figure 27. Sales Market Share of Gastric Carcinomas Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Gastric Carcinomas Drugs by Type in 2025
Figure 29. Market Share of Gastric Carcinomas Drugs by Type (2020-2025)
Figure 30. Market Share of Gastric Carcinomas Drugs by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Gastric Carcinomas Drugs Market Share by Application
Figure 33. Global Gastric Carcinomas Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Gastric Carcinomas Drugs Sales Market Share by Application in 2025
Figure 35. Global Gastric Carcinomas Drugs Market Share by Application (2020-2025)
Figure 36. Global Gastric Carcinomas Drugs Market Share by Application in 2025
Figure 37. Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Gastric Carcinomas Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025)
Figure 40. North America Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 43. North America Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 45. U.S. Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Gastric Carcinomas Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Gastric Carcinomas Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Gastric Carcinomas Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Gastric Carcinomas Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 53. Europe Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 55. Germany Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Gastric Carcinomas Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Gastric Carcinomas Drugs Market Size by Region in 2024
Figure 68. China Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 79. South America Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 80. South America Gastric Carcinomas Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 82. Brazil Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Gastric Carcinomas Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Gastric Carcinomas Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Gastric Carcinomas Drugs Market Size by Region in 2024
Figure 92. Saudi Arabia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Gastric Carcinomas Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Gastric Carcinomas Drugs Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Gastric Carcinomas Drugs Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Gastric Carcinomas Drugs Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Gastric Carcinomas Drugs Market Share Forecast by Type (2026-2035)
Figure 111. Global Gastric Carcinomas Drugs Sales Forecast by Application (2026-2035)
Figure 112. Global Gastric Carcinomas Drugs Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Gastric Carcinomas Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Gastric Carcinomas Drugs Market Size (M USD), 2025-2035
Figure 5. Global Gastric Carcinomas Drugs Market Size (M USD) (2020-2035)
Figure 6. Global Gastric Carcinomas Drugs Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Gastric Carcinomas Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Gastric Carcinomas Drugs Product Life Cycle
Figure 13. Gastric Carcinomas Drugs Sales Share by Manufacturers in 2025
Figure 14. Global Gastric Carcinomas Drugs Revenue Share by Manufacturers in 2025
Figure 15. Gastric Carcinomas Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Gastric Carcinomas Drugs Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Gastric Carcinomas Drugs Revenue in 2025
Figure 18. Industry Chain Map of Gastric Carcinomas Drugs
Figure 19. Global Gastric Carcinomas Drugs Market PEST Analysis
Figure 20. Global Gastric Carcinomas Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Gastric Carcinomas Drugs Market Share by Type
Figure 27. Sales Market Share of Gastric Carcinomas Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Gastric Carcinomas Drugs by Type in 2025
Figure 29. Market Share of Gastric Carcinomas Drugs by Type (2020-2025)
Figure 30. Market Share of Gastric Carcinomas Drugs by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Gastric Carcinomas Drugs Market Share by Application
Figure 33. Global Gastric Carcinomas Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Gastric Carcinomas Drugs Sales Market Share by Application in 2025
Figure 35. Global Gastric Carcinomas Drugs Market Share by Application (2020-2025)
Figure 36. Global Gastric Carcinomas Drugs Market Share by Application in 2025
Figure 37. Global Gastric Carcinomas Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Gastric Carcinomas Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Gastric Carcinomas Drugs Market Size by Region (2020-2025)
Figure 40. North America Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 43. North America Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 45. U.S. Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Gastric Carcinomas Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Gastric Carcinomas Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Gastric Carcinomas Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Gastric Carcinomas Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 53. Europe Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 55. Germany Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Gastric Carcinomas Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Gastric Carcinomas Drugs Market Size by Region in 2024
Figure 68. China Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 79. South America Gastric Carcinomas Drugs Sales Market Share by Country in 2024
Figure 80. South America Gastric Carcinomas Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Gastric Carcinomas Drugs Market Size by Country in 2024
Figure 82. Brazil Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Gastric Carcinomas Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Gastric Carcinomas Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Gastric Carcinomas Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Gastric Carcinomas Drugs Market Size by Region in 2024
Figure 92. Saudi Arabia Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Gastric Carcinomas Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Gastric Carcinomas Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Gastric Carcinomas Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Gastric Carcinomas Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Gastric Carcinomas Drugs Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Gastric Carcinomas Drugs Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Gastric Carcinomas Drugs Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Gastric Carcinomas Drugs Market Share Forecast by Type (2026-2035)
Figure 111. Global Gastric Carcinomas Drugs Sales Forecast by Application (2026-2035)
Figure 112. Global Gastric Carcinomas Drugs Market Share Forecast by Application (2026-2035)
